Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-19

Clinical Trial Update: A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating abrocitinib tablets for atopic dermatitis in India has completed, and the trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abrocitinib (CIBINQO) (Abrocitinib)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19